Beyond Salvage: When to Move to CAR T in Relapsed DLBCL

Opinion
Video

Panelists discuss, when evaluating chimeric antigen receptor T-cell (CAR T) therapy for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), how key considerations include the patient’s fitness, disease burden, prior treatment response, and timing of referral. The limitations of traditional salvage therapy, with historically poor outcomes, must be weighed against CAR T’s potential for durable remissions despite its risks and complexities.

Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content